{"id":148054,"date":"2021-12-22T19:11:25","date_gmt":"2021-12-22T19:11:25","guid":{"rendered":"https:\/\/precoinnews.com\/?p=148054"},"modified":"2021-12-22T19:11:25","modified_gmt":"2021-12-22T19:11:25","slug":"cramers-investing-club-recent-drop-in-a-portfolio-drug-stock-only-a-minor-setback","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/business\/cramers-investing-club-recent-drop-in-a-portfolio-drug-stock-only-a-minor-setback\/","title":{"rendered":"Cramer's Investing Club: Recent drop in a portfolio drug stock only a minor setback"},"content":{"rendered":"

(This article was sent first to members of the CNBC Investing Club with Jim Cramer. To get the real-time updates in your inbox, <\/em>subscribe here<\/em>.)<\/em><\/p>\n

After the big run last week, Eli Lilly (LLY) shares have backed off to a bit to the mid-$260s due to a combination of investors booking profits where they had them in a volatile market and rotational pressure from the risk-on attitude of Tuesday's rally.<\/p>\n

What sent shares of Eli Lilly to new highs last week, including a roughly 10% gain on a single day, was an Investor Day event that was nothing short of impressive. They raised 2021 revenue and earnings per share guidance above consensus thanks to additional revenue from Covid antibodies sales. And their 2022 outlook was much better than what anyone expected.<\/p>\n

See, heading into the event, many analysts feared 2022 would be a down earnings year for Lilly due in part to a reduction in Covid antibody revenue and a step up in investment to fund their large phase 3 programs and support their massive new product launches. But Eli Lilly put an end to that narrative last week.<\/p>\n